axicabtagene ciloleucel
gilead,daiichi sankyo
['zuma-7']
live from #ash22- in zuma-7 subsequent 3l car t-cell therapy after initial response in the 2l appeared to yield improved outcomes in pts with r/r lbcl, but due to the small study size, no conclusions can be made. what did you think of these results? 